The Treatment of Localized Prostate Cancer in Everyday Practice in Germany

A Multicenter Prospective Observational Study (HAROW) in 2957 Patients

Jan Herden, Lena Ansmann, Nicole Ernstmann, Dietrich Schnell, Lothar Weißbach

SUMMARY

Background: Prostate cancer is now often diagnosed in the localized, well-differentiated stage. In the HAROW study, we investigated the care situation with respect to the various treatment options for localized prostate cancer in everyday clinical practice in Germany.

Method: Study physicians for this prospective, multicenter observational study were recruited through the Federation of German Urologists. At six-month intervals, clinical variables were recorded (T category, prostate-specific antigen [PSA], Gleason score, d’Amico risk profile, Charlson Comorbidity Index [CCI]) and patients filled out questionnaires (QLQ-C30) regarding their indication-related quality of life (QoL). Covariance analysis was used to adjust for the variable distribution of patient features among the treatment groups.

Results: Data from 2957 patients were available for analysis. The mean follow-up time was 28.4 months overall, and 47.6 months in the active surveillance (AS) group. Younger patients and patients with a CCI of 0 or 1 predominated in the AS and surgery groups; older patients and patients with a CCI of 2 or above predominated in the groups in which palliative treatment strategies such as hormone therapy (HT) and watchful waiting were applied. The HT group had the highest percentage of patients with a Gleason score of 8 or above (21.2%), while the AS group had the highest percentage of patients with a Gleason score of 6 or below (92.5%), as well as the lowest mean PSA value (5.8 ± 3.4 ng/ml) and the highest percentage of patients with a low-risk profile (82.5%). Of 468 patients in the AS group, 170 (36.3%) underwent a change of treatment. AS and surgery are problematic in that the low metastatic potential and the lack of cancer-specific mortality make it difficult to reach equivalence (11, 12). Prospective randomized trials are problematic in that the low metastatic potential and the lack of cancer-specific mortality make it difficult to reach the patient numbers required for definitive conclusions. A
two-armed study had to be discontinued for this reason (13), and a three-armed trial had to be continued with a lower number of cases (14).

Nevertheless, prospective randomized trials of several treatment strategies have recently been initiated. The German PREFERE study compares AS, OP, RT, and brachytherapy (15), while the British ProtecT trial is investigating AS, OP, and RT (14).

When the efficacy of different treatments is practically the same, other factors become much more important, such as treatment-related adverse effects, quality of life (QoL), the feasibility of the treatments in everyday practice, and cost–benefit considerations. Investigation of these aspects is the task of healthcare research (HCR), which examines “[…] the care of individuals and of the population […] under everyday conditions” (16). HCR data can be used to assess the consequences for daily practice of results obtained in the rather artificial setting of randomized studies.

The HAROW study (HT, AS, RT, OP, WW) is the first urological study of the treatment of localized PCa in Germany (17). It describes the various treatment options in detail and examines the evolution of QoL over time. The AS group was observed with particular interest, because when the study began the strategy of AS was relatively unknown and not widely used.

**Method**

The HAROW study is a multicenter prospective observational study. It was carried out over a 5-year period from July 2008 to July 2013. Of the 259 physicians involved in the study, 86% were urologists in private practice. The criterion for inclusion in HAROW was newly diagnosed cancer confined to the prostate (≤cT2c) with no evidence of metastasis (N0, M0). Data from 2 957 patients were available for analysis.

Because HAROW was conceived as a non-interventional observational study, no restrictions were placed on the type of treatment or how it was carried out. The decision on how to proceed in each individual case was a matter for the patient and the treating physician.

At the outset of the study AS was a novel strategy with no guideline regulating its application.

**TABLE 1**

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Treatment goal</th>
<th>Treatment type</th>
<th>Treatment</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>H</strong></td>
<td>Hormone treatment</td>
<td>Palliation</td>
<td>Defensive</td>
<td>Androgen deprivation by surgical or medicinal castration (androgen receptor antagonists, GnRH analogs, GnRH antagonists)</td>
</tr>
<tr>
<td><strong>A</strong></td>
<td>Active surveillance (AS)</td>
<td>Cure</td>
<td>Defensive, observational</td>
<td>• Digital rectal examination and • PSA determination every 3 months for 2 years, then every 6 months and • Repeat biopsy after 6 months, then every 12 to 18 months for 3 years, subsequently every 3 years</td>
</tr>
<tr>
<td><strong>R</strong></td>
<td>Radiotherapy</td>
<td>Cure</td>
<td>Invasive, definitive</td>
<td>• Percutaneous irradiation (ca. 74 Gy to &lt;80 Gy) • LDR brachytherapy • HDR brachytherapy combined with percutaneous irradiation</td>
</tr>
<tr>
<td><strong>O</strong></td>
<td>Operation</td>
<td>Cure</td>
<td>Invasive, definitive</td>
<td>Radical prostatectomy (RP) • Radical retropubic prostatectomy • Laparoscopic transperitoneal radical prostatectomy • Endoscopic extraperitoneal radical prostatectomy • Robot-assisted radical prostatectomy</td>
</tr>
<tr>
<td><strong>W</strong></td>
<td>Watchful waiting</td>
<td>Palliation</td>
<td>Defensive, observational</td>
<td>Initially no treatment; palliative measures in the event of symptomatic or rapid tumor progression or if requested by the patient</td>
</tr>
</tbody>
</table>

Classification of risk profile according to d’Amico (22): low risk profile: ≤cT2a and PSA ≤ 10 ng/mL and Gleason score ≤ 6; intermediate risk profile: cT2b or PSA 10–20 ng/mL or Gleason score = 7; high risk profile: cT2c or PSA > 20 ng/mL or Gleason score ≥ 8

*Indication for AS: low risk profile (d’Amico) and tumor in ≤ 2 out of 10–12 biopsy samples obtained according to the guidelines and ≤ 50% tumor infiltration per sample

GnRH, Gonadotropin-releasing hormone; PSA, prostate-specific antigen; LDR, low-dose-rate; HDR, high-dose-rate; DGU, Deutsche Gesellschaft für Urologie (German Urological Society)
<table>
<thead>
<tr>
<th>Patients' characteristics at time of study inclusion</th>
<th>HT (n = 204, 6.9%)</th>
<th>AS (n = 468, 15.8%)</th>
<th>RT (n = 486, 16.4%)</th>
<th>OP (n = 1673, 56.6%)</th>
<th>WW (n = 126, 4.3%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>75.3 ± 7.5</td>
<td>75.9 ± 6.1</td>
<td>70.2 ± 6.6</td>
<td>67.8 ± 6.8</td>
<td>72.7 ± 7.5</td>
</tr>
<tr>
<td><strong>Follow-up (months)</strong></td>
<td>29.4 ± 19.9</td>
<td>30.2 ± 19.9</td>
<td>26.8 ± 16.4</td>
<td>29.5 ± 16.6</td>
<td>22.9 ± 15.6</td>
</tr>
<tr>
<td><strong>PSA concentration (ng/mL)</strong></td>
<td>9.4 ± 6.9</td>
<td>9.4 ± 6.9</td>
<td>5.8 ± 2.4</td>
<td>7.7 ± 3.4</td>
<td>8.8 ± 2.4</td>
</tr>
<tr>
<td><strong>Prostate volume (mL)</strong></td>
<td>40.2 ± 13.4</td>
<td>42.5 ± 15.4</td>
<td>30.5 ± 20.7</td>
<td>37.5 ± 26.4</td>
<td>30.7 ± 27.8</td>
</tr>
<tr>
<td><strong>PSA density (ng/mL)</strong></td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.1 ± 0.1</td>
<td>0.5 ± 0.1</td>
<td>0.1 ± 0.1</td>
</tr>
<tr>
<td><strong>CCI</strong></td>
<td>105 (0.6)</td>
<td>43 (2.4)</td>
<td>62 (2.8)</td>
<td>106 (6.3)</td>
<td>42 (2.5)</td>
</tr>
<tr>
<td><strong>n</strong></td>
<td>2031 (68.7)</td>
<td>1405 (48.5)</td>
<td>1223 (72.1)</td>
<td>1213 (72.3)</td>
<td>79 (62.7)</td>
</tr>
<tr>
<td><strong>T category</strong></td>
<td>2.0 (7.1)</td>
<td>1.9 (6.4)</td>
<td>1.9 (6.4)</td>
<td>1.8 (6.2)</td>
<td>1.8 (6.2)</td>
</tr>
<tr>
<td><strong>Gleason score</strong></td>
<td>1619 (64.8)</td>
<td>1481 (64.8)</td>
<td>1384 (65.1)</td>
<td>1330 (61.1)</td>
<td>124 (92.5)</td>
</tr>
<tr>
<td><strong>Risk profile (d'Amico)</strong></td>
<td>292 (68.9)</td>
<td>256 (62.1)</td>
<td>240 (55.6)</td>
<td>240 (55.6)</td>
<td>240 (55.6)</td>
</tr>
</tbody>
</table>

**Deutsches Ärzteblatt International** | Dtsch Arztebl Int 2016; 113: 329–36
Active surveillance in the HAROW study

FIGURE 1

mFU, mean follow-up; lost FU, lost to follow-up

Active surveillance in the HAROW study

- **Beginning of study:** 468 patients (100%)
  - Patients leaving study
    - 112 (23.9%) changed treatment
    - 72 (15.4%) discontinued (lost FU = 23, died = 7, withdrew consent = 24, patient moved away, physician closed office, etc. = 18)

- **End of study:** 284 patients (60.7%) mFU 24.5 months
  - 58 (12.4%) changed treatment
  - 25 (5.3%) discontinued (lost FU = 20, died = 5)

- **End of extended observation AS group:** 201 patients (42.9%) mFU 47.6 months

Data were acquired at the time of recruitment into the study and then at 6-monthly intervals. The physicians recorded clinical parameters, tumor characteristics (findings in digital rectal examination, PSA concentration, Gleason score, risk profile according to D’Amico [22]), details of treatment, disease course, and comorbidities (with the aid of the Charlson Comorbidity Index, CCI [23]). The patients gave written answers to questions about communication by their physician, psychosocial care, and health-related QoL. The QoL was established using module C30 of the Quality of Life Questionnaire (QLQ-C30) of the European Organisation for Research and Treatment of Cancer (EORTC) [24, 25]. This module, developed and validated for use in cancer patients, features a global scale for QoL (rated between 0 and 100) alongside scales for function and symptoms.

A detailed description of the methods can be found in the eBox.

**Results**

The mean observation time was 28.4 months. Further questioning of the AS group up to April 2015 extended the mean observation time to 47.6 months.

The characteristics of the patients at the beginning of the study are shown in Table 2. The younger patients and those with the least comorbidities (CCI = 0–1) are concentrated predominantly in the AS and OP groups, while the older patients and those with the most comorbidities (CCI ≥ 2) are mostly in the palliative HT and WW groups. The non-invasively treated groups (AS and WW) are characterized by relatively low PSA concentrations (5.8 ± 3.4 ng/mL and 6.8 ± 4.9 ng/mL) and low proportions of patients with a Gleason score ≥ 8. The AS group contains most (92.5%) of the patients with a Gleason score ≥ 6 and the majority (82.5%) of those with a low risk profile. Among the patients with a low risk profile, 517/1151 (44.9%) underwent surgery, 14.7% were irradiated, and 37.0% were treated non-invasively (AS or WW).

**Active surveillance**

At the end of the HAROW study in July 2013, 284 (60.7%) of the original 468 patients were still under AS, 112 (23.9%) had switched to another treatment strategy, and 72 (15.4%) had left the study (Figure 1). The reasons for changing treatment were: upgrading on repeat biopsy (n = 52), increased PSA concentration (n = 32), the patient’s wish (n = 17), and the treating physician’s recommendation (n = 6). In five cases no reason was given.

Follow-up of patients under AS was extended to April 2015. By that time a further 58 patients (12.4%) had switched to OP before the end of the HAROW study: 58 (12.4%) of the original 468 patients were still under AS, 112 (23.9%) had switched to another treatment strategy, and 72 (15.4%) had left the study (Figure 1). The reasons for changing treatment were: upgrading on repeat biopsy (n = 52), increased PSA concentration (n = 32), the patient’s wish (n = 17), and the treating physician’s recommendation (n = 6). In five cases no reason was given.

Follow-up of patients under AS was extended to April 2015. By that time a further 58 patients (12.4%) had switched to OP before the end of the HAROW study: 58 (12.4%) of the original 468 patients were still under AS, 112 (23.9%) had switched to another treatment strategy, and 72 (15.4%) had left the study (Figure 1). The reasons for changing treatment were: upgrading on repeat biopsy (n = 52), increased PSA concentration (n = 32), the patient’s wish (n = 17), and the treating physician’s recommendation (n = 6). In five cases no reason was given.

Follow-up of patients under AS was extended to April 2015. By that time a further 58 patients (12.4%) had switched to OP before the end of the HAROW study: 58 (12.4%) of the original 468 patients were still under AS, 112 (23.9%) had switched to another treatment strategy, and 72 (15.4%) had left the study (Figure 1). The reasons for changing treatment were: upgrading on repeat biopsy (n = 52), increased PSA concentration (n = 32), the patient’s wish (n = 17), and the treating physician’s recommendation (n = 6). In five cases no reason was given.

Follow-up of patients under AS was extended to April 2015. By that time a further 58 patients (12.4%) had switched to OP before the end of the HAROW study: 58 (12.4%) of the original 468 patients were still under AS, 112 (23.9%) had switched to another treatment strategy, and 72 (15.4%) had left the study (Figure 1). The reasons for changing treatment were: upgrading on repeat biopsy (n = 52), increased PSA concentration (n = 32), the patient’s wish (n = 17), and the treating physician’s recommendation (n = 6). In five cases no reason was given.
eight patients had a pT3a tumor, and none had a tumor ≥pT3b. Twelve patients from the AS group died during this period—none of them from PCa.

Quality of life
The trends in global QoL—adjusted by patient characteristics—over a period of 3.5 years varied among the treatment groups (Figure 3). The AS group had the highest initial rating (75.56 points, 95% confidence interval [73.43; 77.69]) and maintained this level over time. Patients from the OP and RT groups had lower initial QoL (70.9 points, 95% CI [69.77; 72.03] and 72.82 points, 95% CI [70.52; 75.13] respectively), but over time they approached and eventually attained the level of the AS group. Significant differences between AS and OP were found only in the first year of the study (T0: p = 0.017 and T1: p = 0.018). Between AS and RT no significant differences were observed at all. HT patients had the lowest QoL score at the outset (65.52 points, 95% CI [61.92; 68.91]) and stayed practically constant over time. The QoL of patients in the WW group rose steadily up to T3 (1.5 years) but sank almost back to the initial level thereafter. Only at T3 was there a significant difference (p = 0.007) between WW and HT.

Discussion
The role of invasive procedures in the treatment of localized PCa with a low risk profile remains to be clearly defined. The reasons for this lie in the biological characteristics of the tumor. Tumors with a Gleason score ≤6 appear to have hardly any potential for metastasis, so that OP or RT would represent overtreatment. Two studies, one from the 1980s and one from the 1990s, compared OP with non-intervention (WW) and came to different conclusions after observation for 10 and 13 years respectively. In the PIVOT study, carried out in the USA, the OP strategy achieved higher cancer-specific survival only in patients with an initial PSA concentration >10 ng/mL (11), while the Swedish SPCG-4 study demonstrated superiority of OP only in patients aged <65 years (12). More clinically apparent tumors were included in those studies than would be expected today, because now most tumors are detected by determination of PSA. In the SPCG-4 study 75% of the patients had a palpable tumor (≥T2) and the mean PSA was 13.0 ng/mL. In comparison, the proportion of T2 tumors in the PRIAS study (recruiting only AS patients) is 14.9% (26) and in the HAROW study 39.1%; the mean PSA concentrations are 5.6 ng/mL and 9.4 ng/mL respectively.

HAROW: overall findings
The distribution of T category and the Gleason score in the HAROW study corresponds to the well-known stage shift: non-palpable tumors (≤cT1c = 61.9%) with a Gleason score ≤6 (57.9%) predominate. This is comparable with data from other studies of localized PCa (14, 27). The allocation to the treatment groups shows correct differentiation between curative and palliative strategies, in that younger patients and those with a low CCI score were often treated with AS or OP, while the WW and HT groups are dominated by older patients with high CCI. The high proportion of patients with a low d’Amico risk profile in the AS group (82.5%) and the distinct differences in age and comorbidities between AS and WW seem to show that the participating physicians often selected the AS strategy in accordance with the S3 guideline or the HAROW recommendations. AS was chosen for 33.5% of the patients with a low risk profile, but the fact that OP was preferred for 44.9% of those in this risk category seems to support the overtreatment described in the literature (3, 9).

Active surveillance
Insight into everyday practice is provided by the frequency with which patients switch from AS to other treatment strategies. In a systematic review of 10 clinical AS series embracing a total of more than 3 500 patients, 33% of the patients switched to invasive treatments within the first 5 years (28); in the HAROW study it was 36.3% in just under 4 years. An interesting observation in the HAROW study is the shift from AS to WW. Many study physicians switched patients who for particular reasons (age, comorbidities) were no longer suitable for curative treatment or no longer desired it from AS to the palliative WW strategy. In the first 28.5 months 6.3% of the patients switched to WW, and by 47.6 months the figure was 15.9% (27/170).

Quality of life
Assuming that the various treatment options are oncologically equivalent in low-risk PCa, the anticipated adverse effects and their impact on the patient’s QoL become more
The principal complications of OP are erectile dysfunction (29–100%) and stress incontinence (4–50%) (10), while RT is followed mainly by urogenital (34%) and gastrointestinal (30%) complications (29). Approximately 61% of patients treated with RT are affected by the late complication of erectile dysfunction within 2 years (30). In contrast, a recent systematic review found that patients treated by AS showed high QoL ratings in the absence of serious negative psychological consequences (31). An investigation into quality-adjusted life expectancy showed higher QoL for AS than for invasive forms of treatment (32). The HAROW study is the first in which QoL can be compared longitudinally across all five treatment options. Among the curative strategies, significantly lower QoL than in the AS group was found only for OP patients at T0 and T1, which can be explained by the
intervention and the subsequent phase of convalescence. In the longer term, QoL did not differ significantly among the three curative treatments (AS, RT, OP).

Moreover, the lower QoL was significantly different only for OP patients at two time points (T0, T1). As for the palliative options, the pronounced increase in the QoL of patients in the WW group was seen particularly in the first 1.5 years. Thus, at least in the early phase of treatment there were distinct differences in QoL between WW and HT patients. The predominant lack of significance can be explained by the low case numbers of both groups. For this reason, early HT seems inappropriate in asymptomatic localized PCas, a view supported by the fact that a cohort study with 66,000 low-risk patients found no benefit of early HT in respect of cancer-specific survival (33). Only in patients with advanced PCa was immediate HT associated with improved progression-free survival.

In the AS group, the 88 patients who reached T7 had a QoL rating of 77.68 points at T0, higher than the mean QoL of all AS patients at T0 (75.56 points). This suggests positive selection (attrition bias), a problem that occurs mainly in groups with low numbers of patients. In the WW group, the 19 patients still left at T7 had a QoL rating of 72.22 points at T0 (mean for all WW patients at T0: 69.17 points). Attrition bias was also evident in the HT and RT groups.

Limitations

On the one hand, HCR data consistently yield a lower level of evidence than data from randomized controlled trials (RCTs), largely because of less stringent inclusion criteria and the lack of comparison groups. On the other hand, HCR reflects more accurately the reality of healthcare, which cannot be simulated in RCTs (34). One limitation specific to HAROW is the observation period of 28.4 months (47.6 months for the AS group), relatively short when considering metastasis and tumor-specific mortality for a type of tumor with slow growth. The historical findings were not reviewed by a reference pathologist; however, this is rarely the case in everyday practice. The study physicians were not representative in that due to their participation in HAROW they were acquainted with the (then novel) AS strategy, meaning that bias cannot be excluded.

Conclusions

The results of the HAROW study show that the participating physicians differentiated clearly between curative and palliative treatment strategies. The preference for OP in the majority of tumors with a low risk profile clearly points to overtreatment. A treatment shift—away from OP towards AS—should be targeted in the near future. In addition to diagnosis and advice on management options, urologists in private practice are responsible for an essential part of the treatment in the form of AS. In this context, the revised S3 guideline recommends advancing the time of the first repeat biopsy from 12–18 months to 6 months (10). Since 2014, the British guidelines (35) stipulate multiparametric magnetic resonance imaging before AS.

In a situation where the outcomes of various treatment strategies can be assumed to be similar, non-ontological factors such as QoL, the practicability of treatments, and cost–benefit considerations assume special importance. Herein lies a task for HCR.

It remains to be seen whether the lack of differences in global QoL among the curative forms of treatment will be confirmed in the other dimensions of the EORTC QLQ-C30 (function and symptom scales).

Ethics committee approval

All investigations described in this article took place with the approval of the ethics committee of the Bavarian State Medical Association and adhered to German laws and the Helsinki Declaration of 1975 (current version). All participating patients gave written informed consent.

The HAROW study was initiated and conducted by the Foundation of Men’s Health and financially supported by Gazprom Germania.

Conflict of interest statement

Prof. Weißbach has acted as a paid consultant for the Scientific Institute (Wild) of the AOK health insurance provider. He has received study support (third-party funding) from Gazprom Germania.

The remaining authors declare that no conflict of interests exists.

Translated from the original German by David Roseveare.

Manuscript submitted on 31 July 2015, revised version accepted on 21 December 2015.

REFERENCES


 Corresponding author
 Dr. med. Jan Herden
 Klinik und Poliklinik für Urologie und Kinderurologie
 Universitätsklinikum Köln
 Kerpener Str. 62
 50937 Köln, Germany
 jan.herden@uk-koeln.de

 Supplementary material
 eBook:
 www.aerzteblatt-international.de/16m0329
Supplementary material to:

The Treatment of Localized Prostate Cancer in Everyday Practice in Germany
A Multicenter Prospective Observational Study (HAROW) in 2957 Patients
by Jan Herden, Lena Ansmann, Nicole Ernstmann, Dietrich Schnell, and Lothar Weißbach


Description of methods

The HAROW study was carried out by the Foundation of Men's Health (Berlin) and financially supported by Gazprom Germany. The study physicians were recruited via the Federation of German Urologists (Berufsverband Deutscher Urologen, BDU). Using the address list of the BDU, potential participants were contacted and invited to a HAROW symposium at the 2007 annual congress of the German Urological Society (Deutsche Gesellschaft für Urologie), where all interested parties could register to participate. All those who attended the symposium were subsequently contacted again in writing. Thus, the HAROW physicians comprised an arbitrary sample. The goal of recruiting 250 study physicians was achieved. As for case number planning, it was assumed that 1% of the new patients each year would be recruited. At the 2007 rate of 65,000 new cases per annum this was approximately 3000 patients over 5 years.

The study physicians were urged to enrol their patients consecutively in the study. Nevertheless, participation in the study was an individual decision. Arbitrary decisions on study inclusion cannot be ruled out in healthcare research. Patients who did not take part in the HAROW study were treated normally outside the protocol. Any participant who withdrew his consent after observation for less than 6 months (the first observation time point) was excluded from analysis; for those who withdrew consent later, the data up to the last time point before withdrawal were included. Altogether, 3169 patients were recruited and 212 were excluded from analysis owing to early withdrawal or because they could not be assigned to a primary treatment group.

Missing values were recorded as such and factored into analysis accordingly. Furthermore, adjustments of the data set were undertaken: an expert board scrutinized allocation to the treatment groups; based on individual case decisions, implausible entries for change of treatment, progression, disease course, prostate-specific antigen (PSA), PSA doubling time, T category, and Gleason score were altered.

The disease-specific data were evaluated using the statistics software SPSS version 21. The metric variables were assessed in univariate fashion with analysis of variance, the categorical variables with the chi-square test. The probability of error was assumed to be 5%. In the case of multiple tests no Bonferroni correction was carried out.

The data on QoL were analyzed descriptively by treatment group and over the course of up to 3.5 years. Patients who changed treatment were no longer considered. To adjust for the varying distribution of patient characteristics in the different treatment groups, analyses of covariance (ANCOVA) were calculated in which global QoL was considered as dependent variable, treatment group as factor, and all patient characteristics listed in Table 2 as covariates. The differences among the treatment groups in the adjusted data were tested for significance by means of the Sidak post-hoc test. In the course of adjustment the missing values reduced the number of cases evaluable for QoL to 2,258.